Apellis Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	405.21	466.23	411.29	351.19	551.8	640.19
Short-Term Investments	-	-	-	-	-	60.36
Cash & Short-Term Investments	405.21	466.23	411.29	351.19	551.8	700.55
Cash Growth	13.06%	13.36%	17.11%	-36.36%	-21.23%	-20.18%
Accounts Receivable	440.3	366.22	264.93	206.44	7.73	10.1
Inventory	131.41	142.56	81.4	146.36	85.71	16.29
Other Current Assets	51.11	39.83	31.33	62.34	74.28	97.11
Total Current Assets	1,028	1,015	788.95	766.33	719.52	824.05
Net Property, Plant & Equipment	20.36	19.9	19.04	21.09	24.9	26.08
Other Long-Term Assets	34.15	40.51	77.06	1.31	15.8	31.64
Total Assets	1,083	1,075	885.05	788.73	760.22	881.77
Accounts Payable	49.05	56.8	38.57	37.52	37.34	16.91
Accrued Expenses	133.69	166.05	140.18	127.81	95.14	103.24
Current Portion of Leases	6.96	7.09	6.75	6.44	5.63	4.12
Other Current Liabilities	93.74	93.66	-	75.83	29.5	7.58
Total Current Liabilities	283.45	323.6	185.51	247.59	167.61	131.85
Long-Term Debt	-	-	93.34	93.03	92.74	189.02
Long-Term Leases	12.81	11.95	10.2	11.45	14.35	17.08
Other Long-Term Liabilities	371.35	369.57	367.46	242.13	315.65	345.15
Total Long-Term Liabilities	384.16	381.51	471	346.62	422.74	551.26
Total Liabilities	667.61	705.11	656.51	594.21	590.35	683.1
Common Stock	0.01	0.01	0.01	0	0.01	0.01
Additional Paid-in Capital	3,412	3,385	3,267	3,036	2,480	1,857
Accumulated Other Comprehensive Income	-2.41	-2.1	-3.31	-3.54	-0.88	-2.09
Retained Earnings	-2,994	-3,013	-3,035	-2,837	-2,309	-1,657
Shareholders' Equity	414.92	370.15	228.54	194.52	169.87	198.66
Total Liabilities & Equity	1,083	1,075	885.05	788.73	760.22	881.77
Total Debt	19.77	19.03	110.3	110.93	112.71	210.22
Net Cash (Debt)	385.44	447.2	301	240.26	439.09	490.33
Net Cash Growth	-13.81%	48.57%	25.28%	-45.28%	-10.45%	-1.92%
Net Cash Per Share	2.98	3.44	2.43	2.02	4.14	5.81
Book Value	414.92	370.15	228.54	194.52	169.87	198.66
Book Value Per Share	3.20	2.85	1.84	1.64	1.60	2.35
Tangible Book Value	414.92	370.15	228.54	194.52	169.87	198.66
Tangible Book Value Per Share	3.20	2.85	1.84	1.64	1.60	2.35

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q